Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ricardo Roa Chamorro"'
Autor:
Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez
Publikováno v:
Atherosclerosis Plus, Vol 45, Iss , Pp 32-38 (2021)
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine cl
Externí odkaz:
https://doaj.org/article/b020ee4ca2c84b4e8348c9ae45697a6f
Autor:
Ricardo Roa-Chamorro, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Fernando Jaén-Águila, Pablo González-Bustos, Miguel Ángel Rodríguez-Gil, Juan Diego Mediavilla-García
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown to have a higher risk of presenting atherosclero
Externí odkaz:
https://doaj.org/article/6820c6d5e24b4d3cba0ec2f2c4864085
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 34:285-290
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eee90f50c592b741be1fa30bf9f62411
https://doi.org/10.1016/j.arteri.2022.06.003
https://doi.org/10.1016/j.arteri.2022.06.003
Autor:
Lucía Torres-Quintero, Juan Diego Mediavilla-García, Pablo González-Bustos, Ricardo Roa-Chamorro, José Manuel Puerta-Puerta, Fernando Jaén-Águila
Publikováno v:
Endocrinología, Diabetes y Nutrición. 69:446-450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2668b5fe7881ddfff6ef39ff7dae24c7
https://doi.org/10.1016/j.endinu.2021.03.007
https://doi.org/10.1016/j.endinu.2021.03.007
Autor:
Rodrigo Milán Pinilla, María Magdalena Carrillo Bailén, Marina Blanco-Ruiz, María Josefa Álvarez Soria, Belén Sánchez Rodríguez, Patricia Martínez-Sánchez, Laura Amaya-Pascasio, Roberto Valverde Moyano, Irene Pérez Ortega, María Victoria Mejías Olmedo, Pablo González Bustos, Javier Fernández Pérez, Purificación Sánchez López, Reyes de Torres Chacón, Eduardo Agüera Morales, Manuel Payán Ortiz, Luis Andrade Zumárraga, Antonio Arjona-Padillo, Alba María Castillo Fernández, Cristina Del Toro Pérez, Beatriz Hidalgo Martín, Ricardo Roa Chamorro
Publikováno v:
Atherosclerosis Plus, Vol 45, Iss, Pp 32-38 (2021)
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2169b116cf8566849cf4241055ffa2d5
http://www.sciencedirect.com/science/article/pii/S2667089521000419
http://www.sciencedirect.com/science/article/pii/S2667089521000419
Publikováno v:
Hipertensión y Riesgo Vascular. 38:151-155
Survival of neoplasms has improved significantly in recent years. An increase in the incidence of cardiovascular disease has been observed. This is due to increasing age of patients and the side effects of chemotherapy. Anti-angiogenic drugs frequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::334c142e6814bf67cfece09424bd8f0b
https://doi.org/10.1016/j.hipert.2021.02.003
https://doi.org/10.1016/j.hipert.2021.02.003
Autor:
Ricardo Roa-Chamorro, José M. Puerta-Puerta, Lucía Torres-Quintero, Pablo González-Bustos, Fernando Jaén-Águila, Juan D. Mediavilla-García
Publikováno v:
Revista Sangre. 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::439179d3f13e93765a486506b34c96fa
https://doi.org/10.24875/sangre.22000002
https://doi.org/10.24875/sangre.22000002
Autor:
Ricardo Roa-Chamorro, José M. Puerta-Puerta, Lucía Torres-Quintero, Pablo González-Bustos, Fernando Jaén-Águila, Juan D. Mediavilla-García
Publikováno v:
Revista Sangre (ENG). 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::199533dec5a21bddb157cd5d9bd92e29
https://doi.org/10.24875/sangree.m22000002
https://doi.org/10.24875/sangree.m22000002
Publikováno v:
Hipertensión y Riesgo Vascular. 37:133-136
Autonomic dysfunction is a common condition in the alpha-synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy). Cardiovascular symptoms may include orthostatic hypotension, supine hypertension or decreased heart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1312bc8840ad437e55059fada3d09104
https://doi.org/10.1016/j.hipert.2020.02.006
https://doi.org/10.1016/j.hipert.2020.02.006
Autor:
Lucía Torres-Quintero, Ricardo Roa-Chamorro, Juan Diego Mediavilla-García, Pablo González-Bustos, Carlos García de los Ríos, José Manuel Puerta-Puerta
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 32:66-69
Resumen El desarrollo de enfermedad cardiovascular suele presentarse en sujetos con varios factores de riesgo cardiovascular. Sin embargo, existen otros condicionantes que pueden estar relacionados con la aparicion de enfermedad cardiovascular, como
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a46a4ad874d43d3ac2ccb3813d3fb401
https://doi.org/10.1016/j.arteri.2019.05.002
https://doi.org/10.1016/j.arteri.2019.05.002